Heartburn clinical trials

Explore recruiting heartburn clinical trials.

Recruiting heartburn studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Heartburn trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter study to evaluate the efficacy and safety of 2 doses of linaprazan glurate compared to lansoprazole in 4 or 8 weeks healing in participants with erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D

Germany, Poland, Hungary, Bulgaria, Romania, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A placebo-controlled trial with citalopram for the treatment of typical reflux symptoms in patients with reflux hypersensitivity or functional heartburn with incomplete proton pump inhibitor response.

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

Phase IV, multicenter, open-label, single-arm, open-label study to evaluate the safety of almagate in pregnant women with acidity and heartburn, and on perinatal outcomes in the fetus and newborn

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients: impact of on-demand use, adjustment of therapy or discontinuation.

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D

Hungary, Germany, Romania, Bulgaria, Czechia, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Heartburn trials by city

Heartburn in Toronto Heartburn in Vancouver Heartburn in Montreal Heartburn in Calgary Heartburn in Edmonton Heartburn in Ottawa Heartburn in Winnipeg Heartburn in Quebec City Heartburn in Hamilton Heartburn in Kitchener Heartburn in London Heartburn in Halifax Heartburn in New York Heartburn in Los Angeles Heartburn in Chicago Heartburn in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease